| 1106 |
Use of Longer Oral M/XDR-TB Regimen in Severe Forms of Extrapulmonary TB and TB Meningitis |
02/06/2024 |
DR-TB and PMDT |
| 1107 |
Adverse Drug Reactions due to Longer oral M/XDR-TB Regimen |
02/06/2024 |
DR-TB and PMDT |
| 1108 |
Isoniazid [H] Mono/Poly DR-TB Regimen: Pre-treatment Evaluation |
02/06/2024 |
DR-TB and PMDT |
| 1109 |
Regimen, Duration and Dosage for Isoniazid [H] Mono/Poly DR-TB Regimen |
02/06/2024 |
DR-TB and PMDT |
| 1110 |
Replacement Sequence in the H Mono/Poly DR-TB |
02/06/2024 |
DR-TB and PMDT |
| 1112 |
Use of Isoniazid [H] Mono/Poly DR-TB Regimen in Special Situations |
02/06/2024 |
DR-TB and PMDT |
| 1113 |
Adverse Drug Events: H Mono/Poly DR-TB Regimen |
02/06/2024 |
DR-TB and PMDT |
| 1114 |
Interim Treatment Outcomes of DR-TB Cases |
02/06/2024 |
DR-TB and PMDT |
| 1115 |
Flow Chart of H Mono/Poly DR-TB Patients from Diagnosis to Treatment Outcome |
02/06/2024 |
DR-TB and PMDT |
| 1116 |
Flow Chart of MDR/RR-TB Patients on Shorter Oral Bedaquiline-containing Regimen from Diagnosis to Treatment Outcome |
02/06/2024 |
DR-TB and PMDT |
| 1117 |
Need for Palliative Care in DR-TB Patients |
02/06/2024 |
DR-TB and PMDT |
| 1118 |
Preventive Treatment for Contacts of DR-TB Patients |
02/06/2024 |
DR-TB and PMDT |
| 1230 |
State Programmatic Management of Drug-resistant TB [PMDT] Committee |
02/06/2024 |
DR-TB and PMDT |
| 1233 |
Cascade of Care for DR-TB Patients in the Private Sector |
02/06/2024 |
DR-TB and PMDT |
| 1234 |
Longer Oral M/XDR-TB: Regimen and Duration |
02/06/2024 |
DR-TB and PMDT |
| 1760 |
Diagnosis of DR-TB in Children |
02/06/2024 |
DR-TB and PMDT |
| 1771 |
Classification of Adverse Drug Events |
02/06/2024 |
DR-TB and PMDT |
| 1783 |
Palliative Care approach and benefits in DR-TB |
02/06/2024 |
DR-TB and PMDT |
| 1793 |
Screening among Household Contacts of DR-TB Patients |
02/06/2024 |
DR-TB and PMDT |
| 1799 |
Clinical Diagnosis of Drug Resistance/ Probable DR-TB in Children |
02/06/2024 |
DR-TB and PMDT |
| 1801 |
Laboratory Diagnosis of Drug-resistant TB |
02/06/2024 |
DR-TB and PMDT |
| 1804 |
Treatment Algorithm for MDR/RR-TB |
02/06/2024 |
DR-TB and PMDT |
| 1805 |
Preparation of Patient-wise Boxes [PWB] for DR-TB Patients |
02/06/2024 |
DR-TB and PMDT |
| 1806 |
Distribution of Second-line Drugs from the District Drug Store to the TB Unit Store |
02/06/2024 |
DR-TB and PMDT |
| 1807 |
H Mono/Poly DR-TB Patient Flow from Diagnosis to Treatment Initiation |
02/06/2024 |
DR-TB and PMDT |
| 1808 |
Additional Monitoring During Pregnancy and Lactation in Women on Shorter/Longer Oral MDR-TB Regimen |
02/06/2024 |
DR-TB and PMDT |
| 1815 |
Management of Hepato-toxicity During Treatment with Shorter/Longer Oral MDR-TB Regimen |
02/06/2024 |
DR-TB and PMDT |
| 1820 |
History of Programmatic Management of Drug Resistant TB (PMDT) in India |
02/06/2024 |
DR-TB and PMDT |
| 1822 |
DR-TB Services and Functions of Stakeholders |
02/06/2024 |
DR-TB and PMDT |
| 1847 |
Nodal DR-TB Centre |
02/06/2024 |
DR-TB and PMDT |
